Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Genmab A/S (GMAB) has a Wall Street consensus price target of $40.50, based on estimates from 17 covering analysts. With the stock currently trading at $29.44, this represents a potential upside of +37.6%. The company has a market capitalization of $18.13B.
Analyst price targets range from a low of $34.00 to a high of $48.00, representing a 35% spread in expectations. The median target of $40.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 12 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GMAB trades at a trailing P/E of 15.4x and forward P/E of 23.2x. The forward PEG ratio of 0.80 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow -88.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $214.82, with bear and bull scenarios of $140.87 and $412.91 respectively. Model confidence stands at 39/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how GMAB stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for GMAB is $40.5, representing 37.6% upside from the current price of $29.44. With 17 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
GMAB has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 12 Buy/Strong Buy ratings. The consensus 12-month price target of $40.5 implies 37.6% upside from current levels.
GMAB trades at a forward P/E of 23.1501x, representing a moderate valuation. With analysts targeting $40.5 (37.6% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $48 for GMAB, while the most conservative target is $34. The consensus of $40.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $413 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
GMAB is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 12 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GMAB stock forecast based on 17 Wall Street analysts shows a consensus price target of $40.5, with estimates ranging from $34 (bear case) to $48 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $215, with bear/bull scenarios of $141/$413.
Our quantitative valuation model calculates GMAB's fair value at $215 (base case), with a bear case of $141 and bull case of $413. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 39/100.
GMAB trades at a forward P/E ratio of 23.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 15.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on GMAB, with a "Buy" consensus rating and $40.5 price target (37.6% upside). 12 of 17 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GMAB analyst price targets range from $34 to $48, a 35% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $40.5 consensus represents the middle ground. Our model's $141-$413 range provides an independent fundamental perspective.